OS Therapies' investigational immunotherapy OST-HER2 demonstrates statistically significant benefit in Phase 2b clinical trials for recurrent osteosarcoma, with FDA submission planned for 2025.
OST-HER2 demonstrated a statistically significant 12-month event-free survival (EFS) rate of 33.3% compared to 20% in historical controls for recurrent, fully resected osteosarcoma with lung metastases.